Skip to content

Clinical study of Canna edulis RS3 resistant starch resistant to mild hyperlipidemia clinical research

Clinical study of Canna edulis RS3 resistant starch resistant to mild hyperlipidemia clinical research

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069520
Enrollment
Unknown
Registered
2023-03-20
Start date
2023-03-20
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild hyperlipidemia combined with obesity

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~65 years old, no ethnic limit, no gender limit; 2. Patients diagnosed with mild hyperlipidemia and overweight/obesity: (1) Hypertriglyceridemia (1.7mmol/L=TG<2.3mmol/L); (2) hypercholesterolemia (5.2mmol/L=TC<6.2mmol/L, or 3.4mmol/L=LDL-C<4.1mmol/L); (3) Mixed hyperlipidemia (1.7mmol/L=TG<2.3mmol/L and 5.2mmol/L=TC<6.2mmol/L, or 1.7mmol/L=TG<2.3mmol/L and 3.4mmol/L=LDL-C<4.1mmol/L, or 1.7mmol/L = TG < 2.3mmol/L and 5.2mmol/L = TC <6.2mmol/L and 3.4mmol/ L/ L=LDL-C<4.1mmol/L) (4) Diagnostic criteria for overweight/obesity: BMI= 24 kg/m2; 3. Have communication and cognitive skills, and be able to adhere to long-term medication.

Exclusion criteria

Exclusion criteria: (1) Those who are receiving lipid-lowering drugs; (2) Hyperlipidemia caused by secondary causes, such as nephrotic syndrome, liver disease, hypothyroidism, renal failure, etc.; (3) Severe diabetes, hypertriglyceridemia, cerebrovascular disease and other major diseases that require immediate treatment; (4) Suffering from heart disease, immune system disease, acute onset of chronic diseases, infectious diseases, malignant tumors, etc.; (5) Patients with serious primary diseases and psychosis such as liver, kidney and hematopoietic system; (6) pregnant or lactating women; (7) Those who are allergic and allergic to test drugs; (8) Patients with a history of gallbladder surgery and digestive tract polyp surgery; (9) Those who use antibiotics or take probiotics and other prebiotic preparations within 3 months of recruitment.

Design outcomes

Primary

MeasureTime frame
blood lipids;body composition;waistline;gut microbiota;serum lipid metabolites;bile acid;

Secondary

MeasureTime frame
hepatic and renal function;fasting blood-glucose;fasting insulin;serum inflammatory factors;

Countries

China

Contacts

Public ContactWuyuanhua

The First Affiliated Hospital of Guizhou University of Chinese Medicine

578873682@qq.com+86 18984840873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026